Climb Bio

Q2 FY2026 EarningsQ2 FY2026 results were better than expected as the net loss was narrower than consensus, with GAAP EPS of -$0.18 vs. -$0.21 expected. Operating expenses were well-controlled, and a private placement financing of $110M significantly strengthened the balance sheet, extending the cash runway into H2 2028. Key clinical milestones remain on track, with Phase 1 CLYM116 data expected in September 2026.